on Theranexus (EPA:ALTHX)
THX Pharma and Biocodex conclude a major strategic agreement
On February 12, 2026, in Lyon, THX Pharma (Theranexus), an innovative player in the treatment of rare neurological diseases, announced a webinar to discuss its strategic agreement with Biocodex. This webinar will take place on February 17 at 6:00 PM.
The agreement in question involves licenses acquired by Biocodex, for a potential amount of 173 million euros. It aims at the global development and commercialization of Batten-1, as well as TX01 in North America.
During the webinar, Mathieu Charvériat, CEO, and Julien Veys, Deputy Managing Director, will present THX Pharma's development prospects and the next strategic steps resulting from this partnership.
R. E.
Copyright © 2026 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.
Click here to consult the press release on which this article is based
See all Theranexus news